{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:24:11Z","timestamp":1785522251700,"version":"3.56.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13503-3","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T17:23:11Z","timestamp":1779902591000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world evidence from a tertiary academic center: clinical characteristics, microbiology and outcomes of oncology patients with febrile neutropenia presenting to the emergency department"],"prefix":"10.1186","volume":"26","author":[{"given":"Markus","family":"Kleinberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petar","family":"Popov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pfarrhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Pasalic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kogler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Cacioppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Fuereder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Raderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Brodowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert","family":"Bartsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Prager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Preusser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Minichsdorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"issue":"3","key":"13503_CR1","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1053\/j.seminhematol.2013.06.010","volume":"50","author":"PE Newburger","year":"2013","unstructured":"Newburger PE, Dale DC. Evaluation and management of patients with isolated neutropenia. Semin Hematol. 2013;50(3):198\u2013206. https:\/\/doi.org\/10.1053\/j.seminhematol.2013.06.010.","journal-title":"Semin Hematol"},{"issue":"6","key":"13503_CR2","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","volume":"34","author":"A Kumar","year":"2006","unstructured":"Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589\u201396. https:\/\/doi.org\/10.1097\/01.CCM.0000217961.75225.E9.","journal-title":"Crit Care Med"},{"key":"13503_CR3","doi-asserted-by":"publisher","unstructured":"Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, et al. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol. 2016;27:v111\u201318. https:\/\/doi.org\/10.1093\/annonc\/mdw325.","DOI":"10.1093\/annonc\/mdw325"},{"issue":"1","key":"13503_CR4","doi-asserted-by":"publisher","first-page":"38787","DOI":"10.1038\/s41598-025-22761-1","volume":"15","author":"CB Dracham","year":"2025","unstructured":"Dracham CB, Bandanatham S, Dumpala VRK, Dasari P, Kotlapati S, Juturu V, et al. Microbiological profile and 30-day mortality outcomes in febrile neutropenia among solid malignancy patients: a multicentre retrospective study from resource-limited setting. Sci Rep. 2025;15(1):38787. https:\/\/doi.org\/10.1038\/s41598-025-22761-1.","journal-title":"Sci Rep"},{"issue":"1","key":"13503_CR5","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/1471-2407-11-404","volume":"11","author":"KL Cooper","year":"2011","unstructured":"Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer. 2011;11(1):404. https:\/\/doi.org\/10.1186\/1471-2407-11-404.","journal-title":"BMC Cancer"},{"issue":"8","key":"13503_CR6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/oncolo\/oyac074","volume":"27","author":"R Boccia","year":"2022","unstructured":"Boccia R, Glaspy J, Crawford J, Aapro M. Chemotherapy-induced neutropenia and febrile neutropenia in the US: a beast of burden that needs to be tamed? Oncologist. 2022;27(8):625\u201336. https:\/\/doi.org\/10.1093\/oncolo\/oyac074.","journal-title":"Oncologist"},{"issue":"11","key":"13503_CR7","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1007\/s00520-023-08071-0","volume":"31","author":"B Leon Rapoport","year":"2023","unstructured":"Leon Rapoport B, Garcia-Morillo M, Font C, Samoon Z, Jabbar AA, Kourie HR, et al. A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC neutropenia, infection, and myelosuppression study group initiative. Support Care Cancer. 2023;31(11):628. https:\/\/doi.org\/10.1007\/s00520-023-08071-0.","journal-title":"Support Care Cancer"},{"issue":"5","key":"13503_CR8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3322\/caac.20124","volume":"61","author":"MA Lewis","year":"2011","unstructured":"Lewis MA, Hendrickson AW, Moynihan TJ. Oncologic emergencies: pathophysiology, presentation, diagnosis, and treatment. CA Cancer J Clin. 2011;61(5):287\u2013314. https:\/\/doi.org\/10.3322\/caac.20124.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"13503_CR9","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1086\/339215","volume":"34","author":"WT Hughes","year":"2002","unstructured":"Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34(6):730\u201351. https:\/\/doi.org\/10.1086\/339215.","journal-title":"Clin Infect Dis"},{"issue":"1b","key":"13503_CR10","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1445-5994.2010.02342.x","volume":"41","author":"S Lingaratnam","year":"2011","unstructured":"Lingaratnam S, Slavin MA, Mileshkin L, Solomon B, Burbury K, Seymour JF, et al. An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009. Intern Med J. 2011;41(1b):110\u201320. https:\/\/doi.org\/10.1111\/j.1445-5994.2010.02342.x.","journal-title":"Intern Med J"},{"issue":"7","key":"13503_CR11","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1634\/theoncologist.2011-0456","volume":"17","author":"PM Livingston","year":"2012","unstructured":"Livingston PM, Craike M, Slavin M. Clinical and economic burden of emergency department presentations for neutropenia following outpatient chemotherapy for cancer in Victoria, Australia. Oncologist. 2012;17(7):998\u20131004. https:\/\/doi.org\/10.1634\/theoncologist.2011-0456.","journal-title":"Oncologist"},{"issue":"19","key":"13503_CR12","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1056\/NEJM197105132841904","volume":"284","author":"S Schimpff","year":"1971","unstructured":"Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med. 1971;284(19):1061\u201365. https:\/\/doi.org\/10.1056\/NEJM197105132841904.","journal-title":"N Engl J Med"},{"issue":"5C","key":"13503_CR13","first-page":"13","volume":"80","author":"SC Schimpff","year":"1986","unstructured":"Schimpff SC. Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med. 1986;80(5C):13\u201320.","journal-title":"Am J Med"},{"key":"13503_CR14","doi-asserted-by":"publisher","unstructured":"Kanamaru A, Tatsumi Y. Microbiological data for patients with febrile neutropenia. Clin Infect Dis. 2004;Suppl 39(s1):S7\u201310. https:\/\/doi.org\/10.1086\/383042.","DOI":"10.1086\/383042"},{"issue":"3","key":"13503_CR15","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1086\/598620","volume":"29","author":"SH Zinner","year":"1999","unstructured":"Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis. 1999;29(3):490\u201394. https:\/\/doi.org\/10.1086\/598620.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"13503_CR16","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.cmi.2018.07.026","volume":"25","author":"P Puerta-Alcalde","year":"2019","unstructured":"Puerta-Alcalde P, Cardozo C, Suarez-Lledo M, Rodr\u00edguez-N\u00fa\u00f1ez O, Morata L, Feh\u00e9r C, et al. Current time-to-positivity of blood cultures in febrile neutropenia: a tool to be used in stewardship de-escalation strategies. Clin Microbiol Infect. 2019;25(4):447\u201353. https:\/\/doi.org\/10.1016\/j.cmi.2018.07.026.","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"13503_CR17","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.3390\/microorganisms11102547","volume":"11","author":"M Bachlitzanaki","year":"2023","unstructured":"Bachlitzanaki M, Aletras G, Bachlitzanaki E, Messaritakis I, Koukias S, Koulouridi A, et al. Evaluation of febrile neutropenia in hospitalized patients with neoplasia undergoing chemotherapy. Microorganisms. 2023;11(10):2023. https:\/\/doi.org\/10.3390\/microorganisms11102547.","journal-title":"Microorganisms"},{"issue":"4","key":"13503_CR18","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/bjh.13113","volume":"167","author":"WJFM van der Velden","year":"2014","unstructured":"van der Velden WJFM, Herbers AHE, Netea MG, Blijlevens NMA. Mucosal barrier injury, fever and infection in neutropenic patients with cancer: introducing the paradigm febrile mucositis. Br J Haematol. 2014;167(4):441\u201352. https:\/\/doi.org\/10.1111\/bjh.13113.","journal-title":"Br J Haematol"},{"issue":"6","key":"13503_CR19","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1097\/CCM.0000000000003119","volume":"46","author":"MM Levy","year":"2018","unstructured":"Levy MM, Evans LE, Rhodes A. The surviving sepsis campaign bundle: 2018 update. Crit Care Med. 2018;46(6):997\u20131000. https:\/\/doi.org\/10.1097\/CCM.0000000000003119.","journal-title":"Crit Care Med"},{"key":"13503_CR20","doi-asserted-by":"publisher","unstructured":"Alishahi Tabriz A, Turner K, Hong YR, Gheytasvand S, Powers BD, Elston Lafata J. Trends and characteristics of potentially preventable emergency department visits among patients with Cancer in the US. JAMA Netw Open. 2023;6(1):e2250423. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.50423.","DOI":"10.1001\/jamanetworkopen.2022.50423"},{"issue":"3","key":"13503_CR21","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jemermed.2019.05.023","volume":"57","author":"D Adler","year":"2019","unstructured":"Adler D, Abar B, Durham DD, Bastani A, Bernstein SL, Baugh CW, et al. Validation of the emergency severity index (version 4) for the triage of adult emergency department patients with active Cancer. J Emerg Med. 2019;57(3):354\u201361. https:\/\/doi.org\/10.1016\/j.jemermed.2019.05.023.","journal-title":"The J Emerg Med"},{"issue":"18","key":"13503_CR22","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1200\/JCO.2005.05.645","volume":"23","author":"OAC Clark","year":"2005","unstructured":"Clark OAC, Lyman GH, Castro AA, Clark LGO, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005;23(18):4198\u2013214. https:\/\/doi.org\/10.1200\/JCO.2005.05.645.","journal-title":"J Clin Oncol"},{"issue":"21","key":"13503_CR23","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","volume":"25","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25(21):3158\u201367. https:\/\/doi.org\/10.1200\/JCO.2006.08.8823.","journal-title":"J Clin Oncol"},{"issue":"9","key":"13503_CR24","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/annonc\/mdu203","volume":"25","author":"C Chao","year":"2014","unstructured":"Chao C, Page JH, Yang SJ, Rodriguez R, Huynh J, Chia VM. History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis. Ann Oncol. 2014;25(9):1821\u201329. https:\/\/doi.org\/10.1093\/annonc\/mdu203.","journal-title":"Ann Oncol"},{"issue":"14","key":"13503_CR25","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1200\/JCO.2017.77.6211","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update. J Clin Oncol. 2018;36(14):1443\u201353. https:\/\/doi.org\/10.1200\/JCO.2017.77.6211.","journal-title":"J Clin Oncol"},{"issue":"2","key":"13503_CR26","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/ijc.32249","volume":"146","author":"T Aagaard","year":"2020","unstructured":"Aagaard T, Reekie J, Roen A, Daugaard G, Specht L, Sengel\u00f8v H, et al. Development and validation of a cycle-specific risk score for febrile neutropenia during chemotherapy cycles 2\u20136 in patients with solid cancers: the CSR FENCE score. Intl J Cancer. 2020;146(2):321\u201328. https:\/\/doi.org\/10.1002\/ijc.32249.","journal-title":"Intl J Cancer"},{"issue":"5","key":"13503_CR27","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1200\/JCO.2014.57.2347","volume":"33","author":"A Carmona-Bayonas","year":"2015","unstructured":"Carmona-Bayonas A, Jimenez-Fonseca P, Virizuela Echaburu J, Antonio M, Font C, Biosca M, et al. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the clinical index of stable febrile neutropenia in a prospective cohort of patients from the FINITE study. J Clin Oncol. 2015;33(5):465\u201371. https:\/\/doi.org\/10.1200\/JCO.2014.57.2347.","journal-title":"J Clin Oncol"},{"issue":"17","key":"13503_CR28","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.3390\/jcm12175635","volume":"12","author":"H Shmuely","year":"2023","unstructured":"Shmuely H, Monely L, Shvidel L. All-Cause mortality and its predictors in haemato-oncology patients with febrile neutropenia. J Clin Med. 2023;12(17):2023. https:\/\/doi.org\/10.3390\/jcm12175635.","journal-title":"J Clin Med"},{"issue":"7","key":"13503_CR29","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1093\/annonc\/mdr520","volume":"23","author":"S Schelenz","year":"2012","unstructured":"Schelenz S, Giles D, Abdallah S. Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre. Ann Oncol. 2012;23(7):1889\u201393. https:\/\/doi.org\/10.1093\/annonc\/mdr520.","journal-title":"Ann Oncol"},{"issue":"7","key":"13503_CR30","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1007\/s00520-019-04773-6","volume":"27","author":"P Chambers","year":"2019","unstructured":"Chambers P, Jani Y, Wei L, Kipps E, Forster MD, Wong ICK. Patient factors and their impact on neutropenic events: a systematic review and meta-analysis. Support Care Cancer. 2019;27(7):2413\u201324. https:\/\/doi.org\/10.1007\/s00520-019-04773-6.","journal-title":"Support Care Cancer"},{"issue":"3","key":"13503_CR31","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","volume":"90","author":"GH Lyman","year":"2014","unstructured":"Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol. 2014;90(3):190\u201399. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.12.006.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"12","key":"13503_CR32","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJM199909163411207","volume":"341","author":"PA Pizzo","year":"1999","unstructured":"Pizzo PA. Fever in immunocompromised patients. N Engl J Med. 1999;341(12):893\u2013900. https:\/\/doi.org\/10.1056\/NEJM199909163411207.","journal-title":"N Engl J Med"},{"issue":"6","key":"13503_CR33","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.hoc.2017.08.004","volume":"31","author":"L White","year":"2017","unstructured":"White L, Ybarra M. Neutropenic fever. Hematol Oncol Clin North Am. 2017;31(6):981\u201393. https:\/\/doi.org\/10.1016\/j.hoc.2017.08.004.","journal-title":"Hematol\/Oncol Clinics N Am"},{"issue":"8","key":"13503_CR34","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1634\/theoncologist.12-8-1019","volume":"12","author":"DM Courtney","year":"2007","unstructured":"Courtney DM, Aldeen AZ, Gorman SM, Handler JA, Trifilio SM, Parada JP, et al. Cancer-associated neutropenic fever: clinical outcome and economic costs of emergency department care. Oncologist. 2007;12(8):1019\u201326. https:\/\/doi.org\/10.1634\/theoncologist.12-8-1019.","journal-title":"Oncologist"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13503-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13503-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13503-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:13:13Z","timestamp":1785517993000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13503-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13503"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13503-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"26 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This single-centred, retrospective real-world observational cohort study was approved by the Ethics Committee of the Medical University of Vienna (EC approvals no. Nr.: 1688\/2020) in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Artificial intelligence (AI) tools were utilized to support specific aspects of this study. Open Evidence was used to screen for potential literature. ChatGPT (OpenAI, GPT-5) was employed to assist with R programming for statistical analyses, data visualization and figure generation, as well as to refine the clarity and scientific tone of the manuscript text. All conceptualization, study design, data interpretation and critical reasoning were conducted by the authors. The AI tools served solely as supportive instruments for efficiency and language refinement. All AI-generated content was rigorously reviewed, validated, and edited by the authors, who accept full responsibility for the integrity and accuracy of the final manuscript.","order":2,"name":"Ethics","label":"Statement on the use of artificial intelligence","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.K. received travel support from Eli Lilly Pharmaceutical. M.P. has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, Tocagen, Adastra, Gan & Lee Pharmaceuticals, Janssen, Servier, Miltenyi, B\u00f6hringer-Ingelheim, Telix, Medscape, OncLive, Medac, Nerviano Medical Sciences, ITM Oncologics GmbH, AdAcAp.","order":5,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1397"}}